Trial Profile
Clinical trial of E 10030 for proliferative vitreoretinopathy
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 10 Jul 2019
Price :
$35
*
At a glance
- Drugs Pegpleranib (Primary)
- Indications Proliferative vitreoretinopathy
- Focus Therapeutic Use
- 28 Apr 2014 New trial record